<DOC>
	<DOC>NCT00506701</DOC>
	<brief_summary>Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.</brief_summary>
	<brief_title>Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension</brief_title>
	<detailed_description>Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Clinical diagnosis of Chronic obstructive lung disease Exclusion Criteria Patients with asthma</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>